Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab combination study versus EPd or PVd in relapsed or refractory multiple myeloma
NL-OMON60839Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of talquetamab, teclistamab, pomalidomide, elotuzumab, bortezomib and 1 more in multiple myeloma (MM) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
talquetamabteclistamabpomalidomideelotuzumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON60839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60839.